Compass Therapeutics’ CTX-009 Gains FDA Fast Track Status

Compass Therapeutics (CMPX) has issued an announcement.

Compass Therapeutics, Inc. has announced a significant advancement for its leading drug candidate, CTX-009, which has been granted Fast Track Designation by the U.S. FDA. This promising bispecific antibody, used in combination with paclitaxel, aims to improve treatment for patients with biliary tract cancer, potentially speeding up the development process and review of this innovative therapy. Investors and those following the biotech sector may find this news particularly encouraging as it represents a critical step forward in the drug’s path to market.

For detailed information about CMPX stock, go to TipRanks’ Stock Analysis page.